Stability of CHF during the preceding 3 months (no hospitalization due to CHF, stable CHF medication)
Male or female aged \> 18 years
Written informed consent prior to study participation
The subject is willing and able to follow the procedures outlined in the protocol
You may not be if
Lack of informed consent
Pregnant and lactating females
Acute moderate-severe exacerbation of COPD, acute respiratory failure (pH \< 7,35 and/ or respiratory rate \> 30/min within 3 months prior to inclusion)
Unstable heart failure or planned change in medication (hospitalization due to CHF within 3 months prior to inclusion), any angina pectoris
Not symptomatic
Patient has been committed to an institution by legal or regulatory order
Participation in a parallel interventional clinical trial
Any COPD maintenance therapy before start of randomization
History or diagnosis of Asthma
LVEF \<35 % or ICD or pacemaker
Myocardial infarction 6 months prior inclusion
History of life-threatening arrhythmias (e.g. NSVT or ventricular tachycardia, aFib, AV-Block, pacemaker treatment etc.)
History of diagnosis of Thyrotoxicosis
Chronic kidney disease with an crea-clearance ≤30 ml/min
History of significant alcohol or drug abuse, as judged by the Investigator
Fibrotic lung disease (e.g. IPF, ILD)
Contraindications for MRT (e.g. pacemaker, defibrillator, ferromagnetic metal implants, tattoos, claustrophobia, etc. according to MRI checklist used in the clinical routine)
